Nordion Signs Letter of Intent to Divest MDS Nordion S.A.

Ottawa (ots/PRNewswire) - Nordion Inc. , a leading
provider of products and services to the global health science
market, today announced it has signed a non-binding letter of
agreement with Best Medical International Inc. for the divestiture of
MDS Nordion S.A.

The MDS Nordion S.A. operations currently support four lines of
business out of the Fleurus, Belgium location.

- Agiris - Non-destructive testing equipment and sources
- Glucotrace - FDG imaging agent
- TheraSphere - Targeted liver cancer radiotherapeutic
- Radiochemical business - Generic cyclotron and reactor isotopes

The Letter of Agreement for the divestiture will include three
lines of business and exclude the TheraSphere business which will be
retained by Nordion Inc. It is expected that proceeds received for
the divested operations will be nominal and that Nordion will leave
sufficient working capital in the business to support its operations
through an initial transition period.

During this process, MDS Nordion S.A. remains focused on
continuing to deliver quality product to its customers and managing
the business operations.

In July, 2010, Nordion initiated an Intention to Restructure of
its operations in Fleurus, Belgium. This announcement triggered a
process required under Belgium law to be conducted prior to any
restructuring activity decisions being taken. With the signing of
this recent agreement, the Intention to Restructure process will be
paused until the negotiations with the potential acquirer have
concluded at which time a decision will be made in the best interest
of the Company and its employees.

About Nordion Inc.

Nordion Inc. is a global health science company that provides
market-leading products and services used for the prevention,
diagnosis and treatment of disease. We are a leading provider of
innovative technologies for use in medical imaging and
radiotherapeutics, and sterilization technologies benefiting the
lives of millions of people in more than 60 countries around the
world. Our products and services are used daily by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals,
clinics and research laboratories. Nordion has more than 600 highly
skilled employees in four locations. Find out more at
http://www.nordion.com.

For further information:
MEDIA:
Tamra Benjamin
+1(613)592-3400 x. 1022
tamra.benjamin@nordion.com
INVESTORS:
Ana Raman
+1(613)595-4580
investor.relations@nordion.com

ots Originaltext: Nordion Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information: MEDIA: Tamra Benjamin,
+1(613)592-3400x. 1022, tamra.benjamin@nordion.com; INVESTORS: Ana
Raman, +1(613)595-4580,investor.relations@nordion.com